Saturday, 15 March 2025
  
Login

Australia's most trusted
source of pharma news

Saturday, 15 March 2025
News

Astellas carves niche for Xtandi

Posted 13 March 2025 PM

Astellas has carved out an earlier prostate cancer treatment setting for Xtandi as generics circle the company’s top earning drug in Australia.

Last month, the TGA approved the androgen receptor pathway inhibitor (ARPI) for patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC) with biochemical recurrence at high-risk for metastasis (high-risk BCR), marking the first and only ARPI approved for the indication in Australia.

To see the whole article, please login

Popular

Where HCPs are feeling fresh pain
Drug safety alert extended to men
Drug racing to $1 billion on PBS
Worst off-label offenders targeted
Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (1)

Sales & Customer Relations (37)

Clinical & Medical, R&D (14)

Regulatory, Pharmacovigilance & QA (1)

Other (19)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2025 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home